emtricitabine, rilpivirine hydrochloride and tenofovir disoproxil fumarate

CHEBI:CHEBI_749825

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

active_ingredient_name
RILPIVIRINE HYDROCHLORIDE
rxcui
1147337
product_type
DRUG FOR FURTHER PROCESSING
marketing_category
DRUG FOR FURTHER PROCESSING
listing_expiration_date
20251231
route
ORAL
dosage_form
TABLET, FILM COATED
active_ingredient_strength
300 mg/1
unii
212WAX8KDD
nui
N0000009947
pharm_class_epc
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
pharm_class
Non-Nucleoside Analog [EXT]
pharm_class_moa
Nucleoside Reverse Transcriptase Inhibitors [MoA]
pharm_class_cs
Nucleosides [CS]
package_marketing_start_date
20110810
labeler_name
Gilead Sciences, Inc.
manufacturer_name
Gilead Sciences, Inc.
generic_name
emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
product_ndc
63285-301
marketing_start_date
20110810
spl_id
ba0655a3-17fc-47bf-a155-a5084550fb4a
package_ndc
63285-301-01
package_description
80 BOTTLE in 1 CONTAINER (63285-301-01) / 30 TABLET, FILM COATED in 1 BOTTLE
brand_name
COMPLERA
brand_name_base
COMPLERA
application_number
NDA202123
spl_set_id
d637cfab-f1e8-4eb3-a1b3-f85ca3bec612
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class